Avastin use patent is invalidated by PTAB

All five claims of US patent 7,622,115 – covering methods for treating cancer with Roche’s Avastin (bevacizumab) oncology treatment – have been declared as invalid by the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office (USPTO), following inter partes review proceedings initiated by Hospira.